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Introduction 
 
The World Health Organization (WHO) estimates that 9.6 million cases of tuberculosis (TB) 
occurred in 2014 (corresponding to 133 cases per 100,000 population) with 1,5 million deaths [1]. 
Furthermore, 3.3% of new and 20% of previously treated cases harbour multidrug-resistant (MDR-) 
TB strains. Eastern European and central Asian countries still have the highest prevalence of MDR-
TB. In low TB incidence countries (largely covering North America and Western Europe, Figure 1) 
155,000 TB cases occur every year with over 10,000 deaths [2].   
 
Rapid diagnosis and effective treatment of newly diagnosed TB cases, the majority of whom are 
susceptible to first-line anti-TB drugs, constitutes the essence of TB control by curing the patient of 
TB and rapidly halting further transmission of in the community [3].  It is widely recognised that 
MDR- and XDR- (extensively drug resistant) TB emergence and spread is largely driven by 
mismanagement of misadventures in diagnosis, treatment and control of TB, which is compounded 
by inadequacy of necessary human and financial resources at different levels [3,4 
 
In the last 24 months the WHO published two core documents focusing on the importance of the 
correct case- management of TB: the ‘End Tuberculosis Strategy’ and the ‘Framework towards TB 
Elimination in low incidence countries’ [3,6]. Both documents emphasise the importance of prompt 
diagnosis and effective treatment of newly diagnosed TB cases. 
Although there are recently published International Standards for TB Care and their European 
adaptation [7-9], and the WHO is presently updating its Treatment Guidelines [10], major 
international scientific societies have a critical role to play in the development and implementation 
of  case management guidelines for TB due to their wide membership and access to considerable 
clinical experience of utilising recommendations. Consequently, the American Thoracic Society 
(ATS) and the European Respiratory Society (ERS) have developed TB guidelines [11,12] focused 
predominantly on TB care in settings without significant resource limitations, which have now been 
updated. Using GRADE (Grading of Recommendations, Assessment, Development and Evaluation) 
methodology, the American Thoracic Society (ATS), Centers for Disease Control and Prevention 
(CDC), and Infectious Diseases Society of America (IDSA) jointly sponsored the development of a 
new Treatment of Drug-Susceptible Tuberculosis clinical practice guidelines, which has been 
subsequently endorsed by both the European Respiratory Society (ERS) and the U.S. National 
Tuberculosis Controllers Association, and published in July 2016 in Clinical Infectious Diseases 
[13].   
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As before these guidelines are aimed at providing recommendations on the clinical and public 
health management of TB in adults and children in settings where diagnostic tests and drugs are 
available on a routine basis and without restrictions.  
  
Process and methods 
 
A selected panel of experts, managed for pertinent conflicts of interest according to strict criteria set 
by the participating Societies, with the necessary competencies, skills and perspectives (pulmonary 
medicine, infectious diseases, pharmacokinetics, pediatrics, primary care, public health and 
systematic review methodology) participated as part of the writing committee. 
Nine PICO questions (Population, Intervention, Comparators, Outcomes) viewed by the writing 
committee as key clinical questions in the management of active TB, and their associated 
recommendations were developed based on the evidence that was appraised using GRADE [14,15], 
and are summarized in Table 1. This editorial provides a brief summary of the panel’s 
recommendations; additional important information providing context and references for each 
recommendation, as well as detailed guidance on the management of TB in special populations, 
treatment of tuberculosis in the presence of HIV infection, TB in children, TB during pregnancy 
and breastfeeding, extrapulmonary TB among other clinical situations is available online in the full 
text version of the guidelines  [13].  Additional detailed guidance on the practical aspects of anti-TB 
treatment, drug-drug interactions, therapeutic drug monitoring (TDM) and management of adverse 
events is also available online in the full text version of the guideline. 
 
What are the principles of anti-TB chemotherapy? 
 
Anti-TB treatment aims to cure the patient, prevent complications and death, avoid relapses, reduce 
the transmission potential to susceptible individuals and limit the emergence and spread of drug-
resistant strains. For all these reasons, the therapeutic approach to TB requires the use of multiple 
drugs [12]. 
 
A key responsibility of clinicians is making the decision to initiate appropriate treatment for TB.  
Clinicians decide to start anti-TB chemotherapy based on a variety of data, including clinical, 
radiographic, laboratory, patient and public health criteria.  Commonly, empirical treatment is 
initiated prior to having definitive confirmation of M. tuberculosis, so as to minimize morbidity and 
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to halt further transmission in the community. Today, fortunately, molecular tests offer rapid 
diagnosis before culture results are available [16]. 
Once initiated, treatment success depends upon many factors, and increased risk of relapse has been 
described among patients with extensive disease (i.e., cavitations or extensive infiltrates on chest 
radiograph) [17-21], and/or slow response to treatment (i.e., culture conversion at 2 or 3 months) 
[18,22-24].  
We summarise below the rationale and recommendations of the different PICO Questions. 
 
 
Case management interventions (PICO question 1) 
 
The evidence supports the use of case management strategies in the treatment of TB. In order to 
ensure patient’s adherence and maximize the potentialities for treatment success it is recommended 
to assign a public health nurse and/or a treatment supporter [13], with whom an individualized “case 
management plan” is designed, according to a patient-centred approach, as recommended by the 
ISTC document [7-9], based on the following elements: 1) educating the patient on the different 
aspects of treatment and potential adverse events; 2) discussing treatment monitoring procedures 
and 3) fostering infection control measures, using simple terms and cultural mediators if necessary 
(Table 1). 
 
Directly Observed Therapy (DOT; PICO question 2) 
 
The evidence supports the use of DOT in the treatment of TB. Numerous systematic reviews have  
been conducted to compare outcomes between self-administered therapy (SAT) and DOT (the 
practice of observing the patient swallow their anti-TB drugs). However, DOT is a part of a 
multifaceted public health intervention and as such is not amenable to conventional clinical trials 
approaches assessing benefits/risks.  The systematic review conducted to obtain evidence in support 
of the ERS-endorsed ATS/CDC/IDSA practice guideline did not find any differences between SAT 
and DOT when assessing mortality, treatment completion, and relapse, however, DOT was 
significantly associated with improved treatment success (the sum of patients cured and patients 
completing treatment) and with increased sputum smear conversion during treatment, as compared 
to SAT.  As such, these and other international guidelines support the use of DOT, provided in a 
patient-centred approach, as one component, of TB case management [7-10].  
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The administration schedule of preferred treatment regimens for drug-susceptible TB (PICO 
questions 3-4) 
 
The preferred regimen for treating adults with TB caused by strains known or suspected to be drug-
susceptible consists of an intensive phase of 2 months (isoniazid (INH), rifampicin (RIF), 
pyrazinamide (PZA) and ethambutol (EMB) followed by a continuation phase of 4 months (INH 
and RIF)  [25-27]. Four drugs during the intensive phase of treatment ensure its effectiveness in 
case of INH mono-resistance [13]. 
 
If drug susceptibility test (DST) results are known and the patient’s isolate is susceptible to both 
INH and RIF, EMB is not essential and can be discontinued, in this case the intensive phase is 
composed of INH, RIF and PZA. Pyridoxine (vitamin B6) is given with INH to patients at risk of 
neuropathy (e.g., pregnant women; breastfeeding infants; HIV-coinfected individuals; elderly, 
patients with diabetes, alcoholism, malnutrition or chronic renal failure).  
 
The recommended frequency of treatment administration is once daily for both the intensive and 
continuation phases (see PICO Questions 3 and 4). However, some experts believe that 5 day-a-
week drug administration by DOT is an acceptable alternative to 7 days-a-week. Other alternative 
regimens that are variations of the preferred regimen, which may be acceptable in certain clinical 
and/or public health situations are available in the full text version of the guideline [13].  
 
During treatment, a sputum specimen for direct smear and culture examination are recommended at 
monthly intervals until two consecutive specimens are negative on culture.  As culture status at the 
completion of the intensive phase of treatment (2 months) has been shown to correlate with the 
likelihood of relapse after completion of treatment for pulmonary TB, culture conversion needs to 
be assessed at the end of the two months of treatment in new cases [21,28-30]. Cavitation on the 
initial chest radiograph has also been shown to be a risk factor for relapse [21,31]. In patients with 
cavitation at baseline failing to convert culture after the intensive phase of treatment, rates of 
relapse have been shown to be higher than among patients with neither factor (20% vs. 2% [21,29]), 
and based on expert opinion, the extension of the continuation phase with INH and RIF for an 
additional 3 months (i.e., a continuation phase of 7 months, corresponding to a total of 9 months of 
therapy) is an option left to the physician in discussion with the patient. Additional factors to be 
considered in deciding to prolong treatment in patients with either cavitation or a positive culture at 
2 months (but not both) might include being underweight (>10%), or active smoker, having 
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diabetes, HIV infection, or other immunosuppressing condition; or having extensive disease on 
chest radiograph [30, 32-36]. 
 
 
Treatment in special situations  
 
Detailed recommendations on the management of TB in special situations are available online in the 
full text version of this guideline [13]. Five PICO questions with summary recommendations 
pertinent to the management of tuberculosis in HIV patients, steroid use in pericardial or meningeal 
tuberculosis, and culture-negative TB are summarized below and in Table 1.  
 
HIV infection 
Detailed guidance on the management of TB in HIV-infected patients is provided in the new 
guidelines, including recommendations on the optimal initiation of antiretroviral therapy (ART), the 
management of potential drug-drug interactions, especially between rifamycins and ART, 
paradoxical reactions among others complexities involved in management of HIV/TB. Several key 
features are summarized here. 
 
Based on data that show significant reductions in mortality and AIDS-defining illnesses, patients 
with HIV infection and TB should receive ART in conjunction with daily anti-TB drugs. For HIV-
infected patients receiving ART, the standard 6-month daily anti-TB regimen is recommended. 
In the uncommon situation in which an HIV-infected patient does not receive ART during anti-TB 
treatment, the new ATS/CDC/IDSA guidelines suggest extending the continuation phase (INH and 
RIF) for an additional 3 months (i.e., a continuation phase of 7 months in duration, corresponding to 
a total of 9 months) for treatment of drug-susceptible pulmonary TB (PICO Question 5, Table 1).  
As high rates of relapse and the emergence of drug resistance has been associated with the use of 
intermittent regimens, resulting in low serum concentrations of key component drugs in the setting 
of low CD4 lymphocyte count (<100/mm
3
), based on systematic reviews treatment of HIV-related 
TB should be administered daily in both the intensive and continuation phases. 
 
On the basis of systematic review and meta-analysis, high quality evidence exists showing that 
benefits outweigh harms; the guidelines recommend that patients with tuberculosis and HIV co-
infection receive ART during anti-TB treatment. ART should ideally be started within 2 weeks for 
those patients with a CD4 count <50/mm
3
 and by 8 to 12 weeks for those with a CD4 count 
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>50/mm
3
 (see PICO Question 6). However, in HIV-infected patients with TB meningitis, ART is 
not initiated in the first 8 weeks of anti-TB therapy due to an associated with increased rates of 
adverse events and higher mortality [37]. The concurrent administration of ART and rifamycins is a 
major treatment challenge, and details on the co-administration of these medications, including the 
use of rifabutin (RFB), are available online in the full-text version of the guidelines [13]. 
 
Patients with TB and HIV co-infection are at increased risk of developing paradoxical worsening of 
symptoms, signs, or clinical manifestations of tuberculosis after beginning anti-TB and 
antiretroviral treatments, known as immune reconstitution inflammatory syndrome (IRIS). More 
common in patients with earlier ART initiation and CD4+ cell counts < 50 cells/mm3 [38], IRIS 
may include high fever, worsening respiratory symptoms, inflammation and increased size of 
involved lymph nodes, new lymphadenopathy, expanding central nervous system lesions, 
worsening of pulmonary parenchymal infiltrations, new or increasing pleural effusions, and 
development of intra-abdominal or retroperitoneal abscesses [39].  
 
Management of IRIS is symptomatic. Based on expert opinion, for most patients with mild IRIS, 
anti-TB and antiretroviral therapies can be continued adding anti-inflammatory drugs such as 
ibuprofen. For patients with worsening pleural effusions or abscesses, drainage is indicated. For 
more severe cases of IRIS, corticosteroid treatment is effective. In a trial of prednisone for patients 
with moderate IRIS, prednisone 1.25 mg/kg/day significantly reduced the need for hospitalization 
or surgical procedures [40]. For patients developing IRIS, prednisone may be administered at a dose 
of 1.25 mg/kg/day (50-80 mg/day) for 2-4 weeks, with tapering over a period of 6-12 weeks or 
longer.  
 
Co-trimoxazole (trimethoprim-sulfamethoxazole) prophylaxis has been shown to reduce morbidity 
and mortality in HIV-coinfected patients with newly diagnosed TB [41-43]. WHO recommends co-
trimoxazole for all HIV-infected individuals with active TB regardless of their CD4 cell count [44], 
while in high-income countries co-trimoxazole is primarily used in HIV-infected patients with CD4 
counts <200 cells/mm3 [45]. The use of ART during anti-TB treatment in HIV co-infected patients 
also reduces mortality rates significantly while decreasing the risk of developing AIDS-related 
conditions.  
 
 
TB pericarditis 
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Based on systematic reviews conducted in support of the guidelines, informed greatly by a recent 
placebo-controlled randomized clinical trial with 1400 participants [46], adjunctive corticosteroids 
should not be used routinely in the treatment of patients with pericardial TB (PICO Question 7) [46-
50].  However, selective use of corticosteroids in patients who are at the highest risk for 
inflammatory complications might be appropriate.  
 
TB meningitis 
Treatment for TB meningitis includes INH, RIF, PZA, and EMB in the initial 2-month phase. In the 
continuation phase of treatment, for meningitis due to strains known or presumed to be drug-
susceptible, INH and RIF should be continued for an additional 7-10 months, although the optimal 
duration of chemotherapy is not defined (12 months in the UK). Expert opinion suggest that 
repeated lumbar punctures may be used to monitor changes in CSF cell count, glucose, and protein, 
especially in the early phases of treatment. In children with TB meningitis, the regimen 
recommended consists of INH, RIF, PZA and ethionamide, if possible, or an aminoglycoside, for 2 
months followed by 7 to 10 months of INH and RIF [51]. For adults, based on expert opinion, the 
guidelines recommend using EMB as the fourth drug composing the regimen. 
 
The role of adjunctive corticosteroid therapy in the treatment of TB meningitis has been 
investigated by numerous studies [52-64], and the updated systematic review conducted in support 
of the guidelines showed a mortality benefit from the use of adjuvant corticosteroids. Therefore, the 
guidelines recommend adjunctive corticosteroid therapy with dexamethasone or prednisolone 
tapered over 6-8 weeks for patients with TB meningitis (PICO Question 8). 
 
Culture-negative pulmonary TB in adults 
 
Based on a systematic review conducted in support of the guideline, a 4-month treatment regimen 
was shown to be adequate for sputum smear-negative, culture-negative pulmonary TB (PICO 
Question 9).  The intensive phase of treatment includes INH, RIF, PZA, and EMB daily and 
continued even when the initial bacteriologic studies are negative. If all cultures on adequate 
samples are negative (culture-negative TB) and there is clinical or radiographic response after 2 
months of intensive phase therapy, the continuation phase with INH and RIF may be shortened to 2 
months in HIV-negative adults (but the quality of evidence for this recommendation is very low). 
Alternatively, if there is concern about the adequacy of work-up or the accuracy of the 
microbiologic evaluations, a standard six-month regimen remains preferred [7,8]. Importantly, the 
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guidelines note that causes of failure to isolate organisms should be considered and these include 
the recent use of antibiotics with bactericidal activity against M. tuberculosis (e.g., 
fluoroquinolones), low bacillary populations, inadequate sputum specimens, temporal variations in 
the number of expelled bacilli, overgrowth of cultures with other microorganisms, and errors in 
specimen processing [65]. At a minimum, patients suspected of having pulmonary TB have two 
sputum specimens (using sputum induction with hypertonic saline if necessary) for Alcohol Acid 
Fast Bacilli smears and cultures for mycobacteria or for rapid molecular testing for M. tuberculosis 
as part of the diagnostic evaluation. Bronchoscopy with bronchoalveolar lavage and/or biopsy, have 
also to be considered before making a presumptive diagnosis of culture-negative TB.  
 
 
Conclusions 
The main goals of anti-TB treatment are to cure individual patients and minimise transmission of M.  
tuberculosis within the community. The standard 4-drug regimen (INH, RIF, PZA and EMB) 
remains the preferred initial treatment for drug-susceptible pulmonary TB. Treatment needs to start 
even before direct smear microscopy, molecular tests, and mycobacterial culture results are known 
in patients with a high likelihood of having TB and/or who are seriously ill.  
Variations of the preferred regimen that are appropriate in certain public health situations or in 
special clinical situations and additional detailed information on TB treatment are available in the 
full-text version of the guidelines available online at (weblink) [13].  
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Table 1 
 PICO Question Recommendation (R) Comments 
1 Does adding case management* 
interventions to curative therapy improve 
outcomes compared to curative therapy 
alone among patients with tuberculosis? 
*Case management: patient 
education/counseling, field/home visits, 
integration/coordination of care with 
specialists and medical home, patient 
reminders, incentives/enablers. 
 
R1. We suggest using case 
management interventions during 
treatment of patients with 
tuberculosis  
 
Conditional 
recommendation/ Very low 
quality of evidence 
2 Does self-administered therapy (SAT) 
have similar outcomes compared to 
directly observed therapy (DOT) in 
patients with various forms of 
tuberculosis? 
 
R2. We suggest using DOT rather 
than SAT for routine treatment of 
patients with all forms of 
tuberculosis). 
 
Conditional 
recommendation/low 
quality of evidence 
3 Does intermittent dosing in the intensive 
phase have similar outcomes compared to 
daily dosing in the intensive phase for 
treatment of drug-susceptible pulmonary 
tuberculosis? 
 
R3a: We recommend the use of daily 
rather than intermittent dosing in the 
intensive phase of therapy for drug-
susceptible pulmonary tuberculosis  
 
R3b: Use of three times weekly 
therapy in the intensive phase (with 
or without an initial two weeks of 
daily therapy) may be considered in 
patients who are not HIV-infected 
and are also at low risk of relapse 
(pulmonary tuberculosis caused by 
drug-susceptible organisms, that at 
the start of treatment is non-cavitary 
and/or smear negative)  
 
R3c: In situations where daily or 
three times weekly DOT therapy is 
difficult to achieve, use of twice 
weekly therapy after an initial two 
weeks of daily therapy may be 
considered for patients who are not 
HIV-infected and are also at low risk 
of relapse (pulmonary tuberculosis 
caused by drug-susceptible 
organisms, that at the start of 
treatment is non-cavitary and/or 
smear negative)  
 
 
Strong recommendation / 
Moderate quality of 
evidence 
 
 
 
Conditional 
recommendation / Low 
quality of evidence 
 
 
 
 
 
 
 
 
 
 
Conditional 
recommendation / Very 
low quality of evidence) 
 
Note: if doses are missed in 
a regimen using twice 
weekly dosing then therapy 
is equivalent to once 
weekly, which is inferior 
(see PICO Question 4). 
 
 
 
 
 
 
 
 
Page 10 of 19European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
 
 
 
 
 
4 Does intermittent dosing in the 
continuation phase have similar outcomes 
compared to daily dosing in the 
continuation phase in patients with drug-
susceptible pulmonary tuberculosis 
patients? 
 
R4a: We recommend the use of daily 
or three times weekly dosing in the 
continuation phase of therapy for 
drug-susceptible pulmonary 
tuberculosis  
 
R4b: If intermittent therapy is to be 
administered in the continuation 
phase, then we suggest use of three 
times weekly instead of twice 
weekly therapy. 
 
 
 
 
 
 
 
R4c: We recommend against use of 
once weekly therapy with INH 900 
mg and RPT (rifapentin) 600 mg in 
the continuation phase  
 
Strong recommendation / 
Moderate quality of 
evidence 
 
 
 
Conditional 
recommendation / Low 
quality of evidence). This 
recommendation allows for 
the possibility of some 
doses being missed; with 
twice weekly therapy, if 
doses are missed then 
therapy is equivalent to 
once weekly, which is 
inferior 
 
 
 
Strong recommendation / 
High quality of evidence 
 
In uncommon situations 
where more than once-
weekly DOT is difficult to 
achieve, once weekly 
continuation phase therapy 
with INH 900 mg plus RPT 
600 mg may be considered 
for use only in HIV-
negative persons without 
cavitation on chest 
radiography. 
5 Does extending treatment beyond 6 
months improve outcomes compared to 
the standard 6-month treatment regimen 
among pulmonary tuberculosis patients 
co-infected with HIV? 
R5a: For HIV-infected patients 
receiving antiretroviral therapy, we 
suggest using the standard 6-month 
daily regimen consisting of an 
intensive phase of 2 months of INH, 
RIF, PZA and EMB followed by a 
continuation phase of 4 months of 
INH and RIF for the treatment of 
drug-susceptible pulmonary 
tuberculosis  
 
R5b: In uncommon situations in 
which HIV-infected patients do NOT 
receive antiretroviral therapy during 
tuberculosis treatment, we suggest 
extending the continuation phase 
with INH and RIF for an additional 3 
Conditional 
recommendation / Very 
low quality of evidence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conditional 
recommendation / Very 
Page 11 of 19 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
months (i.e., a continuation phase of 
7 months in duration, corresponding 
to a total of 9 months of therapy) for 
treatment of drug-susceptible 
pulmonary tuberculosis  
 
low quality of evidence) 
6 Does initiation of anti-retroviral therapy 
during tuberculosis treatment compared to 
at the end of tuberculosis treatment 
improve outcomes among tuberculosis 
patients co-infected with HIV? 
 
 
R6. We recommend initiating anti-
retroviral therapy during tuberculosis 
treatment. Anti-retroviral therapy 
should ideally be initiated within the 
first 2 weeks of tuberculosis 
treatment for patients with CD4 cell 
counts <50/mm
3
 and by 8-12 weeks 
of tuberculosis treatment initiation 
for patients with CD4 cell counts 
≥50/mm3  
 
Strong recommendation / 
High quality of evidence) 
 
Note: an exception is 
patients with HIV infection 
and tuberculous meningitis 
7 Does the use of adjuvant corticosteroids in 
tuberculous pericarditis provide mortality 
and morbidity benefits? 
R7. We suggest initial adjunctive 
corticosteroid therapy not be 
routinely used in patients with 
tuberculous pericarditis  
 
Conditional 
recommendation / Very 
low quality of evidence 
8 Does the use of adjuvant corticosteroids in 
tuberculous meningitis provide mortality 
and morbidity benefits 
R8. We recommend initial 
adjunctive corticosteroid therapy 
with dexamethasone given for six 
weeks for patients with tuberculous 
meningitis  
 
Strong recommendation / 
Moderate quality of 
evidence 
9 Does a shorter duration of treatment have 
similar outcomes compared to the 
standard 6-month treatment duration 
among HIV-negative patients with 
paucibacillary tuberculosis (i.e., smear 
negative, culture negative)? 
R9. We suggest that a 4-month 
treatment regimen is adequate for 
treatment of HIV-negative adult 
patients with AFB smear- and 
culture-negative pulmonary 
tuberculosis  
 
Conditional 
recommendation / Very 
low quality of evidence 
 
 
Figure 1. TB low-incidence countries <10 cases per 100,00 population (in blue, 2013 data)   
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